Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IA Carboplatin + Caelyx vs IA Carboplatin + Etoposide Phosphate in Recurrent GBM
NCT06356883Phase 2Recruiting
- Sponsor
- Université de Sherbrooke
- Start
- Aug 2025
- Primary completion
- Apr 2027
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in glioblastoma (GBM) comparing IA Carboplatin + IA Caelyx with IA Carboplatin + IA Etoposide Phosphate (2 arms). Primary endpoints: Tumor Response on MRI using the RANO Criteria and Progression-free Survival. Started Aug 2025; status: recruiting.
02
Drugs
pegylated liposomal doxorubicinetoposide phosphate
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06356883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06356883.